Nancy Lurker - Eyepoint Pharmaceuticals President CEO, Independent Director
| EYPT Stock | USD 7.94 0.31 3.76% |
CEO
Ms. Nancy S. Lurker is President, Chief Executive Officer, Independent Director of the Company. She served as President and Chief Executive Officer and a director of PDI, Inc., a NASDAQlisted healthcare commercialization company now named Interpace Diagnostics Group, Inc. From 2006 to 2007, Ms. Lurker was Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporationrationration, the U.S. subsidiary of Novartis AG. From 2003 to 2006, she served as President and Chief Executive Officer of ImpactRx, Inc., a privately held healthcare information company. From 1998 to 2003, Ms. Lurker served as Group Vice President, Global Primary Care Products and Vice President, General Therapeutics for Pharmacia Corporation, now a part of Pfizer, Inc. She also served as a member of Pharmacias U.S. executive management committee. Previously, Ms. Lurker spent 14 years at BristolMyers Squibb Company, rising from a sales representative to Senior Director, Worldwide Cardiovascular Franchise Management. Ms. Lurker serves as chair of the board of directors of X4 Pharmaceuticals, Inc. and as a member of the board of directors of the Cancer Treatment Centers of America, both privately held companies. Ms. Lurker previously served as a member of the boards of directors of publicly held Auxilium Pharmaceuticals, Inc. from 2011 to 2015 and Mallinckrodt Pharmaceuticals, plc from 2013 to 2016, in addition to serving as a director of PDI, Inc. from 2008 to 2015. Ms. Lurker received a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville. Ms. Lurkers role as President and Chief Executive Officer of the Company, as well as her broad ranging experience in the pharmaceutical industry and her track record of maximizing the potential of new therapies and successfully implementing innovative U.S. since 2016.
| Age | 67 |
| Tenure | 8 years |
| Address | 480 Pleasant Street, Watertown, MA, United States, 02472 |
| Phone | 617 926 5000 |
| Web | https://eyepointpharma.com |
Nancy Lurker Latest Insider Activity
Tracking and analyzing the buying and selling activities of Nancy Lurker against Eyepoint Pharmaceuticals stock is an integral part of due diligence when investing in Eyepoint Pharmaceuticals. Nancy Lurker insider activity provides valuable insight into whether Eyepoint Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Eyepoint Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Eyepoint Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Nancy Lurker over three months ago Disposition of 11111 shares by Nancy Lurker of Eyepoint Pharmaceuticals subject to Rule 16b-3 | ||
Nancy Lurker over six months ago Disposition of 7962 shares by Nancy Lurker of Eyepoint Pharmaceuticals at 28.8 subject to Rule 16b-3 |
Eyepoint Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3139) % which means that it has lost $0.3139 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7468) %, meaning that it created substantial loss on money invested by shareholders. Eyepoint Pharmaceuticals' management efficiency ratios could be used to measure how well Eyepoint Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.21 in 2024. Return On Capital Employed is likely to drop to -0.27 in 2024. At this time, Eyepoint Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 372.9 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 17.4 M in 2024.Similar Executives
| Found 11 records | CEO Age | ||
| Mark Rothera | Viracta Therapeutics | 61 | |
| Daniel MBA | Acumen Pharmaceuticals | 54 | |
| Dror Bashan | Protalix Biotherapeutics | 57 | |
| Jason Lettmann | Alx Oncology Holdings | 47 | |
| Malte MD | Hookipa Pharma | 62 | |
| Amy MBA | Terns Pharmaceuticals | 54 | |
| Denise ScotsKnight | Mereo BioPharma Group | 65 | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Paula Ragan | X4 Pharmaceuticals | 54 | |
| Michael Alrutz | Chimerix | 54 | |
| Michael MBA | Chimerix | 51 | |
Management Performance
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.31 |
Eyepoint Pharmaceuticals Leadership Team
Elected by the shareholders, the Eyepoint Pharmaceuticals' board of directors comprises two types of representatives: Eyepoint Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eyepoint. The board's role is to monitor Eyepoint Pharmaceuticals' management team and ensure that shareholders' interests are well served. Eyepoint Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eyepoint Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Jones, Senior Officer | ||
| Jay MD, Chief Officer | ||
| Michael Pine, Chief Officer | ||
| Ramiro MD, Chief Officer | ||
| Nancy Lurker, President CEO, Independent Director | ||
| Dr MS, Interim Director | ||
| Jennifer Leonard, Chief IT | ||
| Anna Kluczewska, President Ltd | ||
| George Elston, Chief Officer | ||
| Dario Paggiarino, Senior Officer | ||
| Ron Esq, Chief Secretary | ||
| Dario MD, Executive Officer | ||
| Said Saim, Chief Officer | ||
| Isabelle Lefebvre, Chief Officer | ||
| Marcia SellosMoura, Senior Leadership | ||
| Michael Maciocio, Senior Operations | ||
| George CPA, Executive CFO | ||
| David MA, Senior Officer |
Eyepoint Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eyepoint Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (2.27) % | ||||
| Operating Margin | (3.11) % | ||||
| Current Valuation | 331.2 M | ||||
| Shares Outstanding | 68.25 M | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 93.48 % | ||||
| Number Of Shares Shorted | 9.25 M | ||||
| Price To Earning | (2.82) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.